Ablatherm: Europe in the forefront

Soon there will be 100 centres in Europe able to treat with Ablatherm HIFU; the “old” continent is now at the forefront of new medical technologies intended to treat localised prostate cancer. Spectacular growth has been observed in the United Kingdom, notably since the announcement of reimbursement by BUPA, the main private medical insurance company in the UK.